Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Short Interest Down 98.5% in June

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) saw a large decline in short interest during the month of June. As of June 30th, there was short interest totaling 2 shares, a decline of 98.5% from the June 15th total of 137 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 2,784 shares, the short-interest ratio is currently 0.0 days.

Enzon Pharmaceuticals Stock Performance

Shares of Enzon Pharmaceuticals stock remained flat at $4.40 during trading on Friday. 4,182 shares of the stock were exchanged, compared to its average volume of 970. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.16 and a current ratio of 2.01. Enzon Pharmaceuticals has a 1-year low of $1.50 and a 1-year high of $11.10. The firm’s fifty day simple moving average is $5.55 and its two-hundred day simple moving average is $5.68. The firm has a market capitalization of $3.26 million, a P/E ratio of -0.64 and a beta of -0.05.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last posted its quarterly earnings results on Monday, May 4th. The biotechnology company reported ($0.84) EPS for the quarter. The company had revenue of $86.54 million during the quarter.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.